Top White House scientist resigns after review finds he demeaned staff
By Tyler Pager,
The Washington Post
| 02. 07. 2022
"Keynote speaker Eric Lander 1" by afagen
is licensed under CC BY-SA 2.0
Eric Lander, President Biden’s top science adviser, resigned Monday night after he acknowledged mistreating his subordinates and apologized for demeaning them, a pattern of behavior that put him at odds with one of Biden’s earliest promises — to run an administration marked by respect and professionalism.
An internal review by the White House found credible evidence that Lander, director of the Office of Science and Technology Policy, bullied staff in violation of the White House’s “safe and respectful workplace policy,” which was intended in part to draw a contrast with the Trump administration.
Lander’s resignation came after the White House struggled throughout the day to explain why he had not quit or been fired, and how that squared with a pledge Biden made on his first day in office. On that day, he told staffers at swearing-in ceremony, “If you are ever working with me and I hear you treat another colleague with disrespect, talk down to someone, I promise you I will fire you on...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...